DND Pharmatech's FAP-Targeted Product Enters Phase 2 Clinical Trial... Milestone Payment Expected

Expansion of Multiple Pipelines Based on FAP Foundational Patents
PMI07, Developed In-House, Also Undergoing Phase 1/2 Clinical Trials in the U.S.

DND Pharmatech announced on July 8, 2026, that its global partner has completed the first patient dosing in a Phase 2 clinical trial in Europe for a FAP (fibroblast activation protein)-targeted PET imaging agent candidate. Accordingly, the company is expected to receive a milestone payment for entering Phase 2, as stipulated in its existing technology transfer agreement.

DND Pharmatech stated on July 8, 2026, that its global radiopharmaceutical partner has completed the first patient dosing in a Phase 2 clinical trial for a FAP-targeted PET imaging agent candidate.

DND Pharmatech company logo image. DND Pharmatech

In September 2021, DND Pharmatech transferred the technology for PMI07, a FAP-targeted PET imaging agent candidate owned by its wholly owned U.S. subsidiary Neuraly, along with related patent rights, to the radiopharmaceutical imaging subsidiary of a leading global company in the European diagnostic imaging field. The total value of the deal amounted to 60.4 million dollars (approximately 91.9 billion KRW).

The candidate that has entered this Phase 2 clinical trial is a separate pipeline currently being developed by the partner. However, under the agreement between the two companies, it is recognized as a licensed product falling within the scope of DND Pharmatech's FAP-targeted foundational patent rights, making it eligible for a milestone payment upon entering Phase 2.

Separately, PMI07, which was directly developed and licensed out by DND Pharmatech, is currently undergoing a Phase 1/2 clinical trial at the University of Texas Southwestern Medical Center (UTSW) in the United States. The trial is being conducted with the participation of co-founder Dr. Martin Pomper and is evaluating various solid tumor patients, including those with colorectal, pancreatic, and gastric cancers.

Seulgi Lee, CEO of DND Pharmatech, said, "Entering Phase 2 in this case demonstrates that multiple licensed products based on our FAP-targeted patents, including PMI07, are simultaneously making progress in clinical development. As various pipeline developments are proceeding smoothly, we expect that the potential for commercialization as a next-generation radiopharmaceutical platform encompassing both diagnostics and therapeutics will be further expanded."

This content was produced with the assistance of AI translation services.